Bindong Liu, Ph.D.
Assistant Professor

CCHDRHIV

(615) 327-6877
Fax (Fax)
1005 Dr. D.B. Todd Boulevard
Harold D. West Basic Sciences,
Room 4012
Nashville, TN  37208

bliu@mmc.edu

CV or Bio (PDF)

1988, B.S, Biochemistry, Jilin University, Changchun, China
1997, Ph.D, Biochemistry, Jilin University, Changchun, China

There are two major focuses of research in our laboratory. The first one is to understand the mechanism of HIV overcoming APOBEC, a kind of host restriction factor against HIV. APOBEC belongs to a family of proteins that have cytidine deaminase activity. There are 10 family members in humans. Among them, APOBEC3G, 3F and 3DE have strong anti-HIV activities. We and others have found that HIV encodes a small protein termed Vif (viral infectious factor) to overcome the APOBECs’ antiviral activities by inducing their degradation through proteosomal degradation pathway. We also found that Cullin 5, a human ubiquitin E3 ligase, was hijacked by HIV Vif to induce APOBEC degradation. In this process, HIV Vif acts as an adaptor protein linking between Cul5 and APOBEC. We are particularly interested in the molecular interaction between Vif and APOBEC. We are going to identify the interaction domain between Vif and APOBEC, and study the molecular composition of their interaction. By understanding their interaction, we could establish an assay to screen a molecule to break the interaction between Vif and APOBEC so that Vif will no longer be able to degrade APOBEC. It will lead to the development of new targets for HIV medications.
Another focus is to establish a robust viral culture system to replicate our candidate virus for HIV gene therapy. The candidate virus is a human non-pathogenic virus. It shares the same transmission pathway with HIV and specifically replicates in CD4+ T cell. These unique features make this virus a potential viral vector to deliver anti-HIV gene to CD4+ T cells, which are HIV’s natural target. However, the usage of the virus as a vector is restricted by the lack of an efficient cell culture system. We are currently adapting this virus to a tissue culture system. Once we establish the robust tissue culture system, we will try to develop this virus as a vector for the purpose of HIV gene therapy.

Bindong Liu, Phuong Thi Nguyen Sarkis, Kun Luo, Yunkai Yu, Xiao-Fang Yu, “Regulation of Apobec 3F and HIV-1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase” J Virol. 2005 Aug;79(15):9579-87.

Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. “Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.” Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9. Epub 2005 Aug 2.

Kun Luo*, Bindong Liu,* Zuoxiang Xiao, Yunkai Yu, Xianghui Yu, Robert Gorelick and Xiao-Fang Yu, “The amino-terminal region of human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging” J Virol. 2004 Nov;78(21):11841-52. (*equally contributed authors)

Bindong Liu, Xianghui Yu, Kun Luo, Yunkai Yu, and Xiao-Fang Yu, “Influence of Primate Lentiviral Vif and Proteasome Inhibitors on Human Immunodeficiency Virus Type 1 Virion Packaging of APOBEC3G” J Virol. 2004 Feb; 78 (4): 2072–2081
Xianghui Yu*, Yunkai Yu*, Bindong Liu*, Kun Luo, Wei Kong, Panyong Mao, Xiao-Fang Yu, “Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex” Science. 2003 Nov 7;302(5647):1056-60. (*equally contributed authors)

Kong W, Tian C, Liu B, Yu XF, “Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector.” J Virol. 2002 Nov;76(22):11434-9.

Yu XF, Liu W, Chen J, Kong W, Liu B, Yang J, Liang F, McCutchan F, Piyasirisilp S, Lai S, “Rapid dissemination of a novel B/C recombinant HIV-1 among injection drug users in southern China” AIDS 2001 Mar 9;15(4):523-5

Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF, “Enhancement primary and secondary cellular immune responses against HIV-1 Gag by DNA expression vectors that target Gag antigen to the secretory pathway” J Virol. 2000 Jul; 74(13): 5997-6005.

Lee YM, Liu B., Yu XF, “Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes” J Virol 1999 Jul; 73 (7): 5654-62

Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF, “Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin” J Virol 1999 Apr; 73 (4): 2901-8

Bindong Liu, Siguo Liu, Xiufang Yuan, et al. “Detection of Infectious Bronchitis Virus By PCR and Molecular Hybridization” Chinese Journal of Veterinary Science 1997, 17 (5): 431-433.

Bindong Liu, Xiangang Kong, Siguo Liu et al. “Study on IBV Detection by ELISA” Chinese Journal of Animal and Poultry Infectious Disease 1997, 1: 36-39.

Lu Jingliang, Kong Xiangang, Liu Bindong, Ning Xide, “Development of monoclonal antibody against EIA donkey leucocyte attenuated virus.” Journal of Equine Veterinary Science 13(2)96(1993)

Xiangang Kong, Bindong Liu, Jingliang Lu, “Study on EIA Diagnosis Kit on EIA Vaccinated Horse” Chinese Journal of Animal and Poultry Infectious Disease 1992, 4: 26-27

Xiangang Kong, Bindong Liu, Jingliang Lu, “Detection of EIA Vaccine Antigen in Horse Serum by McAb.” Chinese Journal of Animal and Poultry Infectious Disease, 1992, 3: 30-32